GoodRx (GDRX)
(Delayed Data from NSDQ)
$6.97 USD
+0.35 (5.29%)
Updated Apr 23, 2024 03:59 PM ET
After-Market: $6.96 -0.01 (-0.14%) 7:58 PM ET
2-Buy of 5 2
C Value C Growth F Momentum D VGM
GoodRx Holdings, Inc. (GDRX) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$8.89 | $14.00 | $5.00 | 33.48% |
Price Target
Based on short-term price targets offered by 18 analysts, the average price target for GoodRx Holdings, Inc. comes to $8.89. The forecasts range from a low of $5.00 to a high of $14.00. The average price target represents an increase of 33.48% from the last closing price of $6.66.
Analyst Price Targets (18)
Broker Rating
GoodRx Holdings, Inc. currently has an average brokerage recommendation (ABR) of 2.11 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 19 brokerage firms. The current ABR compares to an ABR of 2.21 a month ago based on 19 recommendations.
Of the 19 recommendations deriving the current ABR, nine are Strong Buy, representing 47.37% of all recommendations. A month ago, Strong Buy represented 42.11%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 9 | 9 | 8 | 7 | 5 |
Buy | 0 | 0 | 0 | 0 | 0 |
Hold | 9 | 9 | 10 | 10 | 11 |
Sell | 1 | 1 | 1 | 1 | 1 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 2.11 | 2.11 | 2.21 | 2.28 | 2.47 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
4/10/2024 | KeyBanc Capital Markets | Scott Schoenhaus | Strong Buy | Strong Buy |
3/1/2024 | Truist Securities | Jailendra Singh | Hold | Hold |
2/26/2024 | SVB Securities | Michael Cherny | Not Available | Strong Buy |
11/13/2023 | Robert W. Baird & Co. | Vikram Kesavabhotla | Hold | Hold |
11/9/2023 | Not Identified | Not Identified | Hold | Hold |
9/18/2023 | Guggenheim Securities | Jack D Wallace | Not Available | Strong Buy |
8/10/2023 | Evercore Partners | Mark Mahaney | Not Available | Hold |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 2.11 |
ABR (Last week) | 2.11 |
# of Recs in ABR | 19 |
Average Target Price | $8.89 |
LT Growth Rate | 7.90% |
Industry | Medical Services |
Industry Rank by ABR | 94 of 252 |
Current Quarter EPS Est: | 0.09 |